FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.05
+0.24 (+2.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close8.81
Open8.86
Bid8.80 x 1000
Ask9.03 x 800
Day's Range8.86 - 9.12
52 Week Range7.84 - 18.57
Volume183,043
Avg. Volume306,837
Market Cap326.381M
Beta (3Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-4.49
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.57
  • Business Wire22 hours ago

    Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today ann

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Five Prime Therapeutics Inc Earnings Call

  • Business Wire10 days ago

    Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Carol Schafer to its Board of Directors. Ms. Schafer is an industry leader with more than 25 years of investment banking and equity capital markets experience in the biotechnology sector. “We welcome Carol to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.

  • Business Wire10 days ago

    Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting

    – Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors –

  • Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript
    Motley Fool16 days ago

    Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript

    FPRX earnings call for the period ending March 31, 2019.

  • Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks17 days ago

    Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates

    Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press17 days ago

    Five Prime Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...

  • Business Wire17 days ago

    Five Prime Therapeutics Reports First Quarter 2019 Results

    Five Prime Therapeutics, Inc.  , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company’s recent activities.

  • Markit18 days ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding FPRX are favorable, with net inflows of $1.80 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline
    Zacks24 days ago

    Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline

    Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • American City Business Journals25 days ago

    Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

    This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.

  • Business Wirelast month

    Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close.

  • What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory?
    Simply Wall St.last month

    What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory?

    In December 2018, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its latest earnings announcement, which showed company earnings became less negative compared to the previous year's level - gre...

  • Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
    American City Business Journals2 months ago

    Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

    How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FPRX earnings conference call or presentation 26-Feb-19 9:30pm GMT

    Q4 2018 Five Prime Therapeutics Inc Earnings Call

  • Will Five Prime Therapeutics Continue to Surge Higher?
    Zacks2 months ago

    Will Five Prime Therapeutics Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics.

  • MoneyShow2 months ago

    Five Prime Has 5 Drugs in its Pipeline

    Five Prime (FPRX) recently held a quarterly conference call and, importantly, all of the company's timelines remain on track; it has developed a broad pipeline with five drug candidates now in human clinical development, observes John McCamant, biotech expert and editor of The Medical Technology Stock Letter.

  • Business Wire3 months ago

    Five Prime Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics, will present at the 39th Annual Cowen Healthcare Conference on Wednesday, March 13, 2019 at 8:40am ET.

  • Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Five Prime Therapeutics Inc (FPRX) Q4 2018 Earnings Conference Call Transcript

    FPRX earnings call for the period ending December 31, 2018.

  • Business Wire3 months ago

    Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif.-- -- Significant Pipeline Expansion and Strong Clinical Execution in 2018 Phase 3 FIGHT Registrational Trial in Gastric and GEJ Cancer Enrolling Phase 2 Cabiralizumab/ Opdivo ®  Trial in Pancreatic Cancer Enrolling Phase 1 Starts for FPA150, FPT155 and BMS-986258 Multiple Data Readouts in 2019 Five Prime Therapeutics, Inc.   , a clinical-stage biotechnology company focused ...